Edwards Lifesciences (NYSE:EW) Given New $88.00 Price Target at Piper Sandler

Edwards Lifesciences (NYSE:EW) had its price target raised by Piper Sandler from $85.00 to $88.00 in a report released on Friday, Benzinga reports. Piper Sandler currently has a neutral rating on the medical research company’s stock.

EW has been the subject of several other research reports. Mizuho boosted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a buy rating in a report on Thursday, April 11th. Oppenheimer boosted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an outperform rating in a research note on Monday, March 18th. Morgan Stanley increased their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an overweight rating in a research report on Thursday, March 21st. Bank of America raised Edwards Lifesciences from a neutral rating to a buy rating in a research report on Thursday, March 7th. Finally, Evercore ISI lifted their target price on Edwards Lifesciences from $86.00 to $92.00 and gave the company an in-line rating in a research note on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of Moderate Buy and a consensus target price of $92.71.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $85.95 on Friday. The firm’s 50 day simple moving average is $90.27 and its 200-day simple moving average is $79.06. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The firm has a market cap of $51.74 billion, a PE ratio of 37.05, a price-to-earnings-growth ratio of 4.28 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, equities analysts predict that Edwards Lifesciences will post 2.76 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EW. DSM Capital Partners LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $28,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences during the fourth quarter valued at $34,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences during the first quarter valued at $34,000. Pingora Partners LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $38,000. Finally, Operose Advisors LLC boosted its stake in shares of Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after acquiring an additional 452 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.